BioMarin Pharmaceutical

Historical price data

BioMarin Pharmaceutical is a publicly traded biotechnology company (NASDAQ: BMRN) focused on developing and commercializing innovative medicines for rare genetic diseases. With approximately 3,000 employees worldwide and operations in ~80 countries, the company has built a proven track record of bringing first-in-class therapies to market. Their distinctive approach to drug discovery leverages genetic insights to target underlying molecular mechanisms of disease, resulting in category-defining medicines that address significant unmet medical needs in rare disease communities.

BioMarin utilizes a multi-platform approach including proprietary enzyme replacement therapies, advanced gene therapy technologies, protein engineering, and small molecule development, all focused on genetically-defined rare diseases with well-understood underlying biology.

121 drugs in pipeline, 30 in Phase 3

Total raised: $52M

BioMarin competes with major players like Genzyme/Sanofi, Shire/Takeda, and Alexion/AstraZeneca in the rare disease space. The company differentiates itself through its proven track record of commercial success, deep expertise in genetically-defined conditions, global infrastructure, and focus on first-in-class therapies with well-understood biology.